Drug profile · INN
scopolamine
SCOPOLAMINE
scopolamine (SCOPOLAMINE) is a muscarinic acetylcholine receptor m1 antagonist. Associated with Amneal Pharma Europe Ltd. Route of administration: transdermal. Current US regulatory status: approved.
Drug details — scopolamine
- US status
- approved
- Class
- —
- Route
- TRANSDERMAL
- Patents
- 2
- Programs
- 2
- Data quality
- 0.89
Quick answer
scopolamine (SCOPOLAMINE) is a muscarinic acetylcholine receptor m1 antagonist. Associated with Amneal Pharma Europe Ltd. Route of administration: transdermal. Current US regulatory status: approved.
Key facts
Mechanism of action
Muscarinic acetylcholine receptor M1 antagonist
Primary target: Muscarinic acetylcholine receptor M1
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
Pipeline programs
Related & competitor drugs
Related patents
Frequently asked questions
What is scopolamine?
scopolamine (SCOPOLAMINE) is a muscarinic acetylcholine receptor m1 antagonist. Associated with Amneal Pharma Europe Ltd. Route of administration: transdermal. Current US regulatory status: approved.
What is the brand name for scopolamine?
SCOPOLAMINE is a marketed brand name for scopolamine. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of scopolamine?
scopolamine has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.